AIM-HER2
Breast Cancer
Development/CommercialActive
Key Facts
About PathAI
PathAI is a leading AI-powered pathology company that has developed a comprehensive platform, AISight®, for digital pathology image management and AI algorithm deployment. It serves two primary markets: biopharma clients, for whom it provides translational research, clinical trial services, and diagnostic development, and anatomic pathology laboratories, which use its platform for workflow digitization and AI-assisted diagnostics. The company has achieved significant regulatory milestones, including FDA clearance for its AISight® Dx platform for primary diagnosis and FDA qualification for its AIM-MASH tool for clinical trials, and collaborates with major industry players like Labcorp and top biopharma firms.
View full company profileTherapeutic Areas
Other Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Antifibrotic Therapy Program | MeCo Diagnostics | Pre-clinical |
| inPROBE for HER2 | SDS Optic | Clinical Investigation |
| ACT‑BC1 | Anthrocell | Preclinical |
| APA-1000 Breast Thermotherapy System | Medifocus | Phase III |
| Early‑Detection Breast Cancer Screening | Karkinos Healthcare | Market |
| Unnamed Breast Cancer Program | Click Therapeutics | Pilot/Phase 2 |
| Lerociclib (Lerocliclib) | Chemogenics BioPharma | Phase 3 |
| AT-017 | Asieris Pharmaceuticals | Not Specified |
| CDK2 inhibitor | Acellera | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Maveropepimut-S (MVP-S) | BioVaxys | Clinical Evaluation |
| Cannabics® BRST-33 | CNBX Pharmaceuticals | Discovery |